Investors & Media
4 Sep. 2013

Kamada to Present at September Investment Conferences

NESS ZIONA, Israel (September 4, 2013) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that Gil Efron, Kamada's Chief Financial Officer, will deliver a corporate overview at two upcoming investment conferences in New York City.

Rodman and Renshaw's 15th Annual Global Healthcare Conference taking place from September 8-10, 2013 at the Millennium Broadway Hotel. Mr. Efron's presentation will take place on Monday, September 9th at 11:15 a.m. Eastern time.

Morgan Stanley's Global Healthcare Conference taking place from September 9-12, 2013 at the Grand Hyatt New York. Mr. Efron's presentation will take place on Wednesday, September 11th at 11:45 a.m. Eastern time.

The investor slide presentation accompanying Mr. Efron's remarks are available at the Investor Relations section of the Company's website at

About Kamada

Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company's flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International. In addition to Glassia, Kamada has a product line of nine other injectable pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that is in pivotal Phase 2/3 clinical trials in Europe and will be entering Phase 2 clinical trials in the U.S. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.


Gil Efron


Anne Marie Fields